Healthcare-associated infections & antimicrobial use in long-term care facilities (HALT) 2013 Training Day: Lecture 1 Welcome & Introduction to HALT 2013.

Slides:



Advertisements
Similar presentations
The Place of Multiple Sclerosis in the European Union Policy – the example of EMSPs MS Barometer 2008 Christoph Thalheim Secretary General, European MS.
Advertisements

Political Map of Europe. 1. British Isles 2. Nordic Nations 3. Central Western Europe 4. Mediterranean Europe 5. Eastern Europe.
Surveillance report Annual Epidemiological Report on communicable diseases in Europe ECDC Surveillance Unit European Centre for Disease Prevention and.
Erasmus+ Placement (internship) Program Ceren Genç Director, International Cooperation Office Ipek University
L.O TO KNOW WHAT THE EUROPEAN UNION IS AND WHAT COUNTRIES BELONG TO IT. The European Union.
Assessing child-well-being: perspectives and experiences of Health Behaviour in School- Aged Children (HBSC) Study A World Health Organization Cross- National.
Point Prevalence Survey of Hospital- Acquired Infections & Antimicrobial Use in Ireland PPS Data Collector Training April 2012 Background & Introduction.
Y OUNG C YPRIOT I NTERNET USERS : A QUANTITATIVE SURVEY IN THE CONTEXT OF EU K IDS O NLINE (Co-authors: Tatjana Taraszow & Yiannis Laouris) May 2008.
Area Definition III KAM,Bratislava. The European Law Students’ Association Albania ˙ Austria ˙ Azerbaijan ˙ Belgium ˙ Bosnia and Herzegovina ˙ Bulgaria.
EUROPEAN UNION. WHAT Coalition of 30 countries united in ECONOMY World’s largest trading bloc. World’s largest exporter to the world 16 TRILLION *Biggest.
Grants LXIV International Council Meeting 19th – 26th October, Bodrum Turkey.
INTERNATIONALA CONFERENCE Security and Defence R&D Management: Policy, Concepts and Models R&D HUMAN CAPITAL POLICY ASSISTANT PROFESSOR KONSTANTIN POUDIN.
THE EUROPEAN UNION. HISTORY 28 European states after the second world war in 1951 head office: Brussels 24 different languages Austria joined 1995.
THE EUROPEAN UNION. EU  1993 European Union  Main Aims  All states in the EU = a single market  One currency throughout the EU = the Euro  To have.
OVERVIEW AND COMPLETING THE QUESTIONNAIRES - Part 1 LECTURE 2.
THE UTI MODULE LECTURE. To outline the aims of the UTI module To describe the questionnaires LECTURE OBJECTIVES.
Natural gas, and oil sectors in Europe Vaidotas Levickis Fort Worth, Texas 2015.
PREPARING FOR PARTICIPATION IN HALT-2 LECTURE 6. To outline the steps necessary to prepare successfully for the HALT 2013 PPS. LECTURE OBJECTIVES.
The European Union 1 THE EUROPEAN UNION Lesson 2 Where in the world is the European Union?
ELSA Summer Law Schools IV KAM Prague, 3rd to 7th September 2014.
I will: Know how and why the EU was created. Understand the benefits of being part of the EU.
Time line By: Shirley Lin. The story of European Union
E u r o g u i d a n c e A Network of National Resource and Information Centres for Guidance Established in 1992.
E u r o g u i d a n c e A Network of National Resource and Information Centres for Guidance Established in 1992.
Table 1. Numbers and rates of TB cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based Source:
Healthcare-associated infections & antimicrobial use in long-term care facilities (HALT) 2016 Training Day: Lecture 1 Welcome & Introduction to HALT 2016.
Table 1. Criteria for differentiating acute and chronic hepatitis C Suggested citation: European Centre for Disease Prevention and Control. Annual epidemiological.
The European Union Objectives Identify countries within the EU Explain the political and economic structure of the EU What is the importance of.
Table 1. Number and rate of reported confirmed syphilis cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate,
Table 1. Number and rate of Legionnaires’ disease cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based.
CONFIDENTIAL 1 EPC, European Union and unitary patent/UPC EPC: yes EEA: no EU: no (*) (*) Also means no unitary patent Albania, Macedonia, Monaco, San.
France Ireland Norway Sweden Finland Estonia Latvia Spain Portugal Belgium Netherlands Germany Switzerland Italy Czech Rep Slovakia Austria Poland Ukraine.
INTERNATIONAL BUSINESS Unit 2 Business Development GCSE Business Studies.
1 Healthcare Associated Infections & Antimicrobial Consumption in Long-Term Care Facilities. (HALT) Mags Moran & Mary Rooney Community Infection Control.
Table 1. Criteria for differentiating acute and chronic hepatitis B Suggested citation: European Centre for Disease Prevention and Control. Annual epidemiological.
PPS Data Collector Training April 2017
What does the EU do? Who is in the EU?
EUROPEAN UNION – MAKING OFF European Economic Community
Table 1. Reported confirmed hepatitis A cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
DISTRIBUTION AUTOMATIC - GENERATION
Results of the STRUTI project
Figure 1. Number of reported hantavirus infection cases, EU/EEA, 2014
POST-REFERENDUM INFORMATION FOR EUROPEAN COLLEAGUES
Table 1. Reported, confirmed campylobacteriosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes,
Table 1. Number and rate of reported confirmed syphilis cases per 100 000 population by country and year, EU/EEA, 2010–2014 Country
Table 1. Reported confirmed brucellosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
The European Parliament – voice of the people
The European Parliament – voice of the people
ECDC point prevalence survey (PPS)
Gonorrhoea cases of gonorrhoea were reported by 27 EU/EEA Member States for The overall notification rate was 18.8 cases per 100 000 population.
EU: First- & Second-Generation Immigrants
Point prevalence survey epidemiology
Table 1. Table 1. Reported confirmed salmonellosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y.
Table 1. Reported confirmed VTEC infection cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N.
Table 1. Reported confirmed cholera cases, EU/EEA, 2010–2014
Table 1. Reported confirmed botulism cases: number and rate per population, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based Source:
Table 1. Reported confirmed leptospirosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N.
European Union Membership
European representation of respiratory critical care HERMES participants. European representation of respiratory critical care HERMES participants. Countries.
Table 1. Confirmed cases of trichinellosis: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N = no,
Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes  J. Freeman, J. Vernon, K. Morris, S.
Update on Derogation Reporting
Collecting methodological information on regional statistics
Trends for ECDC measles and rubella monitoring,
Tony Crockford & Muhammad Sartaj.
EuroNHID project Scientific Contents
Table 1. Reported confirmed listeriosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
EARS-Net results 2011 Ole Heuer
Table 1. Reported confirmed yersiniosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
Prodcom Statistics in Focus
Presentation transcript:

Healthcare-associated infections & antimicrobial use in long-term care facilities (HALT) 2013 Training Day: Lecture 1 Welcome & Introduction to HALT 2013

Welcome Introductions Housekeeping: –Fire exits –Registration for continuing professional development –ONE completed HPSC questionnaire per participating LTCF –Please switch off/silence mobile phones Today’s schedule

Lecture Objectives To outline the HALT survey and types of surveillance To describe how we define healthcare-associated infections for surveillance To explain reasons for carrying out surveillance in long- term care facilities (LTCFs) and how it is done To provide results of previous HALT surveys in Europe and Ireland To outline the lessons learned from previous HALT surveys

What is HALT? A point prevalence survey in nursing homes/long-term care facilities (LTCF) Commissioned by the European Centre for Disease Prevention and Control (ECDC) –HALT first carried out in May 2010 – Participation in 28 EU countries, including Ireland –Ireland performed a further HALT survey in May 2011 –A further EU HALT to be completed in May 2013

What is my role in HALT? You have been nominated as the local HALT contact person and lead data collector for your LTCF You are responsible for the HALT survey in your LTCF –Trained HALT data collector –Getting ready for HALT in your LTCF – picking the date, picking your team, planning the schedule, informing the staff and residents –Planning and carrying out data collection (with assistance of your colleagues) –As the trained HALT data collector, you need to be present on the HALT date(s) in your LTCF and released from usual duties so you have time to perform HALT –You will need to show your colleagues how HALT survey is conducted if they are helping you with data collection –You will need to make sure that the HALT protocol is followed exactly –After all the data is collected, you will need to ensure it is entered into the HALT software and returned to HPSC by deadline – you will need time to do this

Ireland has excellent participation by LTCF in HALT surveys! In 2010, Irish LTCF accounted for 9.5% of all participating LTCF in European HALT survey!

What is surveillance? Surveillance = ‘keeping an eye on things’ Systematic collection and analysis of data and the use of this information for action –Improve the care we give to our residents/patients –Reduce the occurrence of preventable healthcare- associated infection (HCAI) in our residents –Compare our results with those of other LTCFs that look after a similar type of resident

Surveillance of HCAI Fundamental part of infection prevention & control but requires resources and skilled personnel Two types of surveillance are used in healthcare: 1.Prevalence – specific point in time 2.Incidence – ongoing capture of data HALT is a prevalence survey

What is a healthcare-associated infection? HCAI HCAI = infection that a resident acquires/picks up after being in contact with the healthcare system (e.g., following admission to a LTCF) HCAI may also be used to describe infections picked up in hospital/hospital-acquired infections HALT is only looking at infections acquired in LTCF – hospital infections are not being counted in HALT

How do we decide whether the resident’s infection is a HCAI? For the purposes of HALT, an infection is defined as being acquired in the LTCF (i.e., HCAI) if it starts day three onwards following the resident’s admission to the LTCF EXAMPLE –J Juliet is admitted to LTCF A on May 1 st (DAY 1) and on May 3 rd (DAY 3) she develops signs and symptoms of an infection –Provided J Juliet’s signs and symptoms fit the definition of an infection – her infection is healthcare-associated

What is the difference between infection and colonisation/carriage? Carriage/colonisation = bugs/microorganisms are carried by the resident, but are not currently causing infection Generally, colonisation/carriage in the LCTF resident does not need antimicrobial therapy in the absence of signs/symptoms of infection EXAMPLES: –A resident has a positive nasal swab result for MRSA, but has no signs of infection at that site –A resident with an indwelling urinary catheter has a positive CSU result for E. coli, but has no signs or symptoms of a urinary tract infection –A resident with a chronic venous leg ulcer has a positive ulcer swab with mixed bacterial growth of Pseudomonas aeruginosa, Group C streptococcus and anaerobes, but the ulcer site is unchanged in appearance HALT is not collecting data on colonisation – Only data on HCAI is being collected

What information will be collected in the HALT survey? 1.Healthcare-associated infection (HCAI) 2.Antimicrobial use 3. Antimicrobial resistance in a selected group of microorganisms/bugs 4. Infection prevention and control resources and practices

How do we calculate prevalence? (e.g. for antimicrobial use) Total population of residents in the LTCF on May 7 th Numerator: Number of residents in the LTCF who are on antimicrobials on May 7 th Denominator: Eligible residents in the LTCF on May 7 th Ineligible resident Admitted less than 24 hrs ago

Prevalence of antimicrobial use = 3 ÷ 9 = 0.33 x 100 = 33% i.e 33% of residents are on antimicrobials on May 7 th Numerator: Number of residents in the LTCF who are on antimicrobials on May 7th 3 Denominator: Eligible residents in the LTCF on May 7th 9 How do we calculate prevalence? (e.g. for antimicrobial use)

Prevalence of HCAI Number of residents in the LTCF on May 7 th Number of eligible residents in the LTCF on May 7 th = A Number of eligible residents who have signs or symptoms that meet a definition for a HCAI = B Prevalence of HCAI = B/A x 100 = C% The good news is that the HALT software does all of the calculations for you!

What is meant by an active HCAI? An active HCAI present on the day of the survey is defined as follows: A HCAI is active when signs and symptoms of the infection are present on the survey date OR A HCAI is active when signs and symptoms were present in the past and the resident is (still) receiving treatment for that infection on the survey date HALT 2013 is only collecting information on active HCAI and not on past HCAI

How do we decide whether a resident’s signs and symptoms are a HCAI? For consistency, it is important that we use the same definitions to categorise a resident as meeting the definition for a urinary tract infection in Cork, in Leitrim, in Bordeaux and in Rome HCAI definitions are standardised – we want to compare ‘like-with-like’

An important concept Definitions that are used for surveillance of HCAI are NOT the same as clinical judgement We use standardised HCAI definitions for surveillance/measurement of infections We use clinical judgement on a daily basis to make real-time decisions about our resident’s care We do not use HCAI surveillance definitions for making real-time decisions about our resident’s care

How will my LTCF benefit from taking part in HALT 2013? HALT will help you to gather information for action: HCAI, antimicrobial use and infection control practices and resources in your LTCF The information you gather as part of HALT will help your LTCF to plan improvements in resident care (e.g., development of quality improvement plans or policies and help decide how resources might be best allocated) If your LTCF participated in HALT 2010 and/or 2011, repeating the survey in 2013 will help to compare your LTCF’s local results over time and track improvements Participation in HALT will raise the awareness of the staff in your LTCF on importance of HCAI, antimicrobial use & surveillance

What were the European results of HALT 2010? Total LTCF-beds: 67,613 beds Mean LTCF size: 94 beds (9 – 695 beds) Total eligible population: 63, 884 r. (94.5%) n° eligible residents: < > countries, 722 LTCFs Austria Belgium Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Ireland (9.5%) Italy Lithuania Luxemburg Malta Poland Portugal Slovenia Spain Sweden The Netherlands UK: England, Scotland, Wales, Northern Ireland Source: Katrien Latour ARHAI 2011

EU Results: Resident Risk Factors & Care Load

EU Results: Prevalence of HCAI and Antimicrobial Use Of 61,932 eligible residents: 2,679 on antimicrobial(s) 2,495 had signs/ symptoms of an infection: Of those 1,488 met a definition for a HCAI Source: Katrien Latour ARHAI 2011

Prevalence = number of eligible residents on antimicrobials/number of eligible residents x 100 2,679/ 61,932 x 100 = 4.3% EU Results: Prevalence of antimicrobial use Source: Katrien Latour ARHAI 2011

Infection siteProphylacticTherapeuticTotal Urinary tract % Respiratory tract % Skin or wound % 22.5% Why were residents prescribed antimicrobials? Source: Katrien Latour ARHAI 2011

>7 Crude prevalence of residents with HAI (/100 ER) EU Results: Prevalence of HCAI Prevalence = number of eligible residents who meet a HCAI definition/number of eligible residents x 100 1,488/61,932 x 100 = 2.4% Source: Katrien Latour ARHAI 2011

What were the most common HCAI types in the EU 2010 HALT survey? 1.Respiratory tract infections:33.6% 2.Urinary tract infections:22.3% 3.Skin infections:21.4%

What were the Irish results from HALT surveys conducted in 2010 and 2011? Key Results Number of participating LTCF Public ownership Private ownership Median LTCF size47 beds (range = ) 50 beds (range=10-226) Number of eligible residents4,1705,922 Number of eligible residents on antimicrobials Prevalence of antimicrobial use10.2%10.1% Number of eligible residents meeting HCAI surveillance definitions 149*242* Prevalence of HCAI3.6%4.1% *A resident could have had more than one active HCAI type on survey date

What were the most common HCAI types in the Ireland 2010 & 2011 HALT surveys?

What did we learn from HALT? Participation in HALT raised awareness that HCAI and antimicrobial prescribing are common in Irish LTCF Twice as many residents in Irish LTCF were prescribed antimicrobials as in other EU countries Prescribing antimicrobials for prevention of infections/prophylaxis is a common practice in Irish LTCF –There is poor scientific evidence for prophylaxis –Unnecessary antimicrobials increase risk of resistant microorganisms and increase risk of Clostridium difficile infection UTI was more common in Irish LTCF than in other EU countries

Why are we repeating HALT? Increase the number of participating LTCF Improve quality of data on HCAI, antimicrobial use and infection prevention and control practices and resources Promote education, training and development of guidelines Ultimately – we all want to improve resident care Minimise the risk of harm to our residents by avoiding prescribing of unnecessary antimicrobials and indwelling devices Minimise transmission of antimicrobial resistant microorganisms/bugs and C. difficile within Irish LTCF

What actions did we take after HALT 2010? HPSC –Provided local HALT reports for participating LTCF –Published a national HALT report of results for Ireland –Ireland results provided for inclusion in EU results –Decided to build on HALT 2010 by repeating survey in 2011 –We shared our experience with other EU countries –Dedicated section of HPSC website for HCAI in LTCF –Inclusion of LTCF in national guidelines for prevention and control of MRSA, other multi-drug resistant organisms, C. difficile infection –New guidelines for prevention of catheter-associated urinary tract infection & diagnosis and management of UTI in LTCF residents –New guidelines for antimicrobial prescribing in primary care

Z/MicrobiologyAntimicrobialResistance/InfectionControlandHAI/Surveillance/HCAIinl ongtermcarefacilities/

What actions did you take after HALT?

Thank you for your attention address for queries: